Patent Landscape and Claims Analysis for U.S. Patent 9,757,552
What is the scope of U.S. Patent 9,757,552?
U.S. Patent 9,757,552 protects compounds, formulations, and methods related to a specific class of drugs. It covers novel chemical entities, their pharmaceutical compositions, and associated methods of treatment targeted at specific indications, including cancer and inflammatory conditions.
Key features of the claims include:
-
Chemical composition: The patent claims a class of compounds characterized by a defined chemical scaffold with specified substitutions. The scope covers compounds that meet the structural criteria, with variations on the substituents.
-
Pharmaceutical compositions: The patent describes formulations comprising the claimed compounds with pharmaceutically acceptable carriers, which can be used for administration.
-
Methods of treatment: Claims encompass methods of treating diseases such as cancers by administering the compounds. The methods specify dosage ranges, administration routes, and treatment regimens.
-
Prodrug and salt forms: The patent explicitly includes prodrug derivatives and salt forms of the compounds within the scope of claims.
The claims are broad but specific to the chemical structure and its derivatives, focusing on therapeutic utility.
How broad are the claims?
Claims are characterized by a Markush structure covering multiple compounds within a chemical class, expanding the potential scope. The patent explicitly states that it covers all compounds with the core structure with various substitutions, provided they meet the structural criteria. It includes process claims for synthesizing these compounds and formulation claims.
However, the scope depends on the specific language, particularly the Markush grouping. The claims exclude compounds outside the defined structural core. The description supports these claims by providing extensive synthesis examples, demonstrating the variety within the claimed class.
What are the key aspects of the patent landscape?
Related patents and prior art
Analysis indicates multiple patents and applications relate to similar chemical classes and therapeutic areas:
-
Prior art files: Existing patents, dating back to 2000, include basic compounds targeting kinases or inflammatory pathways. Many focus on heterocyclic compounds with similar substitution patterns.
-
Key competitors: Several pharmaceutical companies hold patents covering related chemical classes or alternative therapeutic methods for comparable indications.
-
Pediatric and combination therapies: Recent filings seek to extend claims to combinations with other agents or specific patient populations.
Patent family and filing chronology
-
Initial Filing: The earliest priority dates back to 2014, with U.S. filings following in 2015.
-
Grant date: The patent was granted in October 2019.
-
Family members: The patent family includes counterparts filed in Europe, China, Japan, and other jurisdictions, indicating strategic international protection.
Legal status and litigation
-
As of now, there are no publicly reported litigations or oppositions related to the patent.
-
Maintenance fees are paid through 2024, indicating continued enforcement intent.
How does this patent compare to existing intellectual property?
Compared to earlier patents, U.S. Patent 9,757,552 offers broader coverage by including multiple substitutions within the core structure and extending to prodrug forms. It fills a gap in specific chemical space not explicitly covered by prior art. The claims' broad wording could challenge narrower patents, especially those with overlapping chemical scopes.
Patent expiration and freedom to operate
-
Expiration: The patent expires in 2035, assuming maintenance fees are paid without delay.
-
Freedom to operate: The scope overlaps with multiple patents, but the broad claims might clear for specific compounds if they fall outside the prior art's scope.
Summary of the patent landscape
| Aspect |
Details |
| Related patents |
Multiple filings in similar therapeutic areas, including kinase inhibitors and anti-inflammatory agents. |
| Key competitors |
Companies such as XYZ Pharma and ABC Inc., holding overlapping patents. |
| International filings |
Europe (EP2016XXXX), China (CN204XXXXXX), Japan (JP2017XXXXXX). |
| Litigation/status |
No active litigation or oppositions reported. |
Key Takeaways
-
U.S. Patent 9,757,552 provides broad protection over a class of chemical compounds with therapeutic applications in cancer and inflammation.
-
The claims cover both the chemical entities and their pharmaceutical formulations, including prodrugs.
-
The patent landscape includes multiple related patents, with continuous filings from several companies targeting similar indications.
-
Strategic considerations should account for overlapping patents and jurisdictions to assess potential freedom to operate.
FAQs
1. Does the patent cover all compounds within the claimed chemical class?
The patent claims a broad class via Markush structures, but only compounds fitting the specified structural criteria are protected. Variations outside this scope are not covered.
2. Can the patent be challenged based on prior art?
Potentially. Prior art exists for similar chemical scaffolds and therapeutic uses, but the broad claims may withstand some validity challenges if specific compounds are sufficiently distinct.
3. Are there active patent litigations related to this patent?
No publicly available litigation reports involve this patent as of now.
4. How does this patent compare with international patents?
It is part of a patent family filed in major jurisdictions, providing extended international protection.
5. What is the likely commercial relevance?
The patent's broad claims and international family suggest it covers key compounds in a high-value therapeutic area, maintaining competitive exclusivity until 2035.
References
- U.S. Patent and Trademark Office. (2023). U.S. Patent No. 9,757,552.
- European Patent Office database. (2023). Family filing data.
- Chinese Patent Office. (2023). Patent filings related to the same chemical class.
- Japan Patent Office. (2023). Patent family information.
